Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together

Anna Wawruszak, Jarogniew Luszczki, Marta Halasa, Estera Okon, Sebastian Landor, Cecilia Sahlgren, Adolfo Rivero-muller, Andrzej Stepulak

Research output: Contribution to journalArticleScientificpeer-review

4 Downloads (Pure)

Abstract

Histone deacetylase inhibitors (HDIs) are promising anti-cancer agents that inhibit proliferation of many types of cancer cells including breast carcinoma (BC) cells. In the present study, we investigated the influence of the Notch1 activity level on the pharmacological interaction between cisplatin (CDDP) and two HDIs, valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA, vorinostat), in luminal-like BC cells. The type of drug–drug interaction between CDDP and HDIs was determined by isobolographic analysis. MCF7 cells were genetically modified to express differential levels of Notch1 activity. The cytotoxic effect of SAHA or VPA was higher on cells with decreased Notch1 activity and lower for cells with increased Notch1 activity than native BC cells. The isobolographic analysis demonstrated that combinations of CDDP with SAHA or VPA at a fixed ratio of 1:1 exerted additive or additive with tendency toward synergism interactions. Therefore, treatment of CDDP with HDIs could be used to optimize a combined therapy based on CDDP against Notch1-altered luminal BC. In conclusion, the combined therapy of HDIs and CDDP may be a promising therapeutic tool in the treatment of luminal-type BC with altered Notch1 activity.
Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume22
Issue number10
DOIs
Publication statusPublished - 2021
MoE publication typeA1 Journal article-refereed

Keywords

  • breast cancer
  • Notch1
  • histone deacetylase inhibitors (HDIs)
  • valproic acid (VPA)
  • vorinostat (SAHA)
  • cisplatin (CDDP)
  • isobolographic analysis

Fingerprint Dive into the research topics of 'Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together'. Together they form a unique fingerprint.

Cite this